GlassScriptPhysician profile
Rahul A Rasheed
NPI 1629364955
$15,402.98
in general payments reported to CMS, 2019-2025
27 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 80% of Surgical Critical Care providers received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2021: $426 · 2022: $11K · 2023: $537 · 2024: $633 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $1,164 · Travel and Lodging: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $1,164.21 |
| Travel and Lodging | $607.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,968.32 | 2022-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Abiomed | $661.01 | 2024-2025 | Impella |
| Getinge USA Sales, LLC | $346.09 | 2025 | Vasoview Hemopro 2, Cardiohelp |
| Tei Biosciences INC | $334.88 | 2019 | |
| Integra Lifesciences Corporation | $297.86 | 2021-2022 | |
| Stryker Corporation | $170.47 | 2022 | |
| Edwards Lifesciences Corporation | $139.02 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.62 | 2022 | |
| Medical Device Business Services, INC. | $123.70 | 2021 | |
| La Jolla Pharmaceutical Company | $121.86 | 2023 | Giapreza |
| Alcresta Therapeutics, INC. | $121.83 | 2024 | Relizorb |
| Avanos Medical | $121.81 | 2019 | |
| Mylan Specialty L.P. | $116.71 | 2021 | |
| Kci USA, INC. | $114.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $111.54 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $109.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $98.37 | 2023 | Andexxa |
| Medtronic, INC. | $69.00 | 2025 | |
| Fisher & Paykel Healthcare INC | $61.96 | 2019 | |
| Acell, INC. | $40.69 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $37.43 | 2019 | |
| Abbott Laboratories | $36.84 | 2024 | Ensite |
| Ethicon US, LLC | $23.86 | 2021 | |
| Davol INC. | $15.46 | 2023 | Arista Ah Flexitip |
| Smith+Nephew, INC. | $14.59 | 2019 | |
| Portola Pharmaceuticals, LLC | $10.87 | 2019 | |
| Z-Medica, LLC | $10.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.